Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Editorial

Create a translational medicine knowledge repository - Research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

Authors: Bruce H Littman, Francesco M Marincola

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Pharmaceutical industry consolidation and overall research downsizing threatens the ability of companies to benefit from their previous investments in translational research as key leaders with the most knowledge of the successful use of biomarkers and translational pharmacology models are laid off or accept their severance packages. Two recently published books may help to preserve this type of knowledge but much of this type of information is not in the public domain. Here we propose the creation of a translational medicine knowledge repository where companies can submit their translational research data and access similar data from other companies in a precompetitive environment. This searchable repository would become an invaluable resource for translational scientists and drug developers that could speed and reduce the cost of new drug development.
Literature
1.
go back to reference Garnier J-P: Rebuilding the R&D Engine in Big Pharma. Harvard Business Review. 2008, 1-9. Garnier J-P: Rebuilding the R&D Engine in Big Pharma. Harvard Business Review. 2008, 1-9.
2.
go back to reference CMR International 2009 Pharmaceutical R&D Factbook, CMR International, a Thomson Reuters Business: 2009 CMR International 2009 Pharmaceutical R&D Factbook, CMR International, a Thomson Reuters Business: 2009
3.
go back to reference Arnst C: Drug Mergers: Killers for Research, Bloomberg Business Week. News Analysis. 2009 Arnst C: Drug Mergers: Killers for Research, Bloomberg Business Week. News Analysis. 2009
4.
go back to reference Littman BH, Williams SA: Opinion: The ultimate model organism: progress in experimental medicine. Nature Reviews Drug Discovery. 2005, 4: 631-638. 10.1038/nrd1800.CrossRefPubMed Littman BH, Williams SA: Opinion: The ultimate model organism: progress in experimental medicine. Nature Reviews Drug Discovery. 2005, 4: 631-638. 10.1038/nrd1800.CrossRefPubMed
6.
go back to reference Littman BH, Krishna R, Editors: Translational Medicine and Drug Discovery. 2011, Cambridge University Press, New York Littman BH, Krishna R, Editors: Translational Medicine and Drug Discovery. 2011, Cambridge University Press, New York
7.
go back to reference Bleavins MR, Rahbari R, Jurima-Romet M, Carini C, Editors: Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy. 2010, John Wiley and Sons, Inc., Hoboken, NJ Bleavins MR, Rahbari R, Jurima-Romet M, Carini C, Editors: Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy. 2010, John Wiley and Sons, Inc., Hoboken, NJ
Metadata
Title
Create a translational medicine knowledge repository - Research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?
Authors
Bruce H Littman
Francesco M Marincola
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-56

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue